Results 51 to 60 of about 882 (153)
, 2018 Vaborbactam (formerly RPX7009) is a novel inhibitor of serine β-lactamases, including Ambler class A carbapenemases, such as KPCs. The current study evaluated the in vitro activity of the combination agent meropenem-vaborbactam ...
Michael N. Dudley +4 more
core +1 more source
Chemical structures of vaborbactam and β-lactams, a monobactam and a DBO inhibitor.
, 2021 Vaborbactam, ceftazidime, cefoperazone, meropenem, aztreonam, and zidebactam are represented. The R1-and R2-groups for ceftazidime are indicated.
Vijay Kumar (377076) +5 more
core +1 more source
Clinical Case Reports, Volume 14, Issue 8, August 2026.ABSTRACT Pan‐drug resistant Klebsiella pneumoniae is a major therapeutic challenge, particularly when standard last‐line agents are unavailable or contraindicated. We report a 45‐year‐old man with multifocal osteomyelitis and persistent purulent wound discharge despite broad‐spectrum antibiotics, repeated debridement, and two sequential amputations ...
Ali Akbar Heydari +2 more
wiley +1 more source
MicrobiologyOpen, Volume 15, Issue 4, August 2026.Novel KPC‐25 and first‐reported KPC‐127 sequentially evolved in one patient under CAZ‐AVI pressure, distinct mutations remodel enzyme activity to drive differential multidrug resistance. ABSTRACT The emergence of novel Klebsiella pneumoniae carbapenemase (KPC) variants contributing to clinical treatment failure poses a substantial threat to public ...
Ke Lei +8 more
wiley +1 more source
Antimicrobial Agents and ChemotherapyCeftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are key therapeutic options for infections caused by KPC-producing Klebsiella pneumoniae (KPC-Kp).
Marta Hernández-García +8 more
doaj +1 more source
Guidelines for Essential Trauma Care: Second Edition (2026)
World Journal of Surgery, Volume 50, Issue 6, Page 1409-1450, June 2026.Injury is a major cause of death and disability globally, with the highest burden in low‐ and middle‐income countries (LMICs). Strengthening the organization and planning for trauma care (care of the injured) can improve care and lower mortality. In 2004, the International Association for Trauma Surgery and Intensive Care (IATSIC) and the World Health ...
Charles Mock +41 more
wiley +1 more source
, 2018 Meropenem–vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic acid β-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE ...
John P Mills +3 more
core +1 more source
Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]
Drugs, 2018 The global threat of the spread of carbapenem resistance in Enterobacteriaceae has led to the search for new antibacterials. Intravenous meropenem/vaborbactam (Vabomere™) is the first carbapenem/β-lactamase inhibitor combination approved in the USA for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis ...
openaire +2 more sources
Metalloids: Semi as Metals yet Full of Antimicrobial Potential
ChemMedChem, Volume 21, Issue 7, 14 April 2026.Metalloids such as boron (B), silicon (Si), germanium (Ge), arsenic (As), antimony (Sb), and tellurium (Te) bridge metals and non‐metals, displaying unique chemical versatility. Recent research highlights their diverse antimicrobial and therapeutic potentials, from natural products to synthetic organic and organometallic molcules, underscoring renewed ...
Kevin Böhm +2 more
wiley +1 more source
Infectious Diseases and Therapy, 2018 Introduction Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations.
Richard G. Wunderink +22 more
doaj +1 more source